Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1991 1
2001 2
2002 2
2003 3
2004 4
2005 7
2006 9
2007 5
2008 12
2009 13
2010 16
2011 14
2012 20
2013 19
2014 11
2015 11
2016 10
2017 12
2018 17
2019 21
2020 11
2021 8
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28930775

172 results

Results by year

Filters applied: . Clear all
Page 1
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamaguchi K, Fujikawa K, Nobuoka T, Okamoto K, Miyamoto H, Muguruma N, Takemasa I, Takayama T. Sato Y, et al. Cancer Chemother Pharmacol. 2019 Jan;83(1):161-167. doi: 10.1007/s00280-018-3719-0. Epub 2018 Nov 7. Cancer Chemother Pharmacol. 2019. PMID: 30406285 Clinical Trial.
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Okuda T, Minami S, Takahashi M, Okamoto T, Takada K, Miyanisi K, Takayama T, Kato J. Uemura N, et al. Cancer Chemother Pharmacol. 2017 Oct;80(4):707-713. doi: 10.1007/s00280-017-3404-8. Epub 2017 Aug 28. Cancer Chemother Pharmacol. 2017. PMID: 28849257 Clinical Trial.
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, Ema A, Ushiku H, Wada T, Washio M, Watanabe A, Higuchi K, Tanabe S, Koizumi W, Watanabe M, Yamashita K. Hosoda K, et al. Gastric Cancer. 2019 May;22(3):598-606. doi: 10.1007/s10120-018-0884-0. Epub 2018 Oct 3. Gastric Cancer. 2019. PMID: 30284080 Clinical Trial.
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Moriwaki T, Hirai S, Hironaka S, Amagai K, Soeda A, Sato M, Nihei T, Hirose M, Matsuda K, Ohkawara A, Yamaguchi T, Ozeki M, Mamiya T, Murashita T, Hyodo I. Moriwaki T, et al. Gastric Cancer. 2014 Apr;17(2):354-61. doi: 10.1007/s10120-013-0284-4. Epub 2013 Jul 13. Gastric Cancer. 2014. PMID: 23852397 Clinical Trial.
172 results